• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 4:03:02 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials
    Get the next $EVGN alert in real time by email
    SC 13G/A 1 d122146dsc13ga.htm EVOGENE LTD Evogene Ltd

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    Amendment No. 8*

    Evogene Ltd

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    M4119S104

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)

    [ ] Rule 13d-1(c)

    [ ] Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No. M4119S104                 13G

     

    1.

    NAME OF REPORTING PERSON (S.S. or I.R.S. Identification No. of Above Person)

     

        

    Ivy Investment Management Company Tax ID No. 03-0481447

     

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

     

      (a)

         [ ]

      (b)

         [ ]

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

    5.      SOLE VOTING POWER    2,757,223 (See Item 4)
    6.      SHARED VOTING POWER    0
    7.      SOLE DISPOSITIVE POWER    2,757,223 (See Item 4)
    8.      SHARED DISPOSITIVE POWER    0

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

        

    2,757,223 (See Item 4)

     

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES:

        

    [ ]

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9: 7.8

     

    12.

    TYPE OF PERSON REPORTING: IA


    CUSIP No. M4119S104                 13G

     

    1.

    NAME OF REPORTING PERSON (S.S. or I.R.S. Identification No. of Above Person)

     

        

    Waddell & Reed Financial, Inc. Tax ID No. 51-0261715

     

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

     

      (a)

        [ ]

      (b)

        [ ]

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

    5.      SOLE VOTING POWER    2,757,223 (See Item 4)
    6.      SHARED VOTING POWER    0
    7.      SOLE DISPOSITIVE POWER    2,757,223 (See Item 4)
    8.      SHARED DISPOSITIVE POWER    0

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

        

    2,757,223 (See Item 4)

     

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES:

        

    [ ]

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9: 7.8

     

    12.

    TYPE OF PERSON REPORTING: HC


    Item 1(a):

    Name of Issuer: Evogene Ltd

     

    Item 1(b):

    Address of Issuer’s Principal Executive Offices:

                           13 Gad Feinstein Street, Park Rehovot P.O.B. 2100

                           Rehovot 7612002

                           Israel

     

    Item 2(a):

    Name of Person Filing:

     

      (i)

    Waddell & Reed Financial, Inc.

      (ii)

    Ivy Investment Management Company

     

    Item 2(b):

    Address of Principal Business Office:

     

      (i)-(ii):

            6300 Lamar Avenue

          

            Overland Park, KS 66202

     

    Item 2(c):

    Citizenship:

     

        

    (i), (ii): Delaware

     

    Item 2(d):

    Title of Class of Securities: Common Stock

     

    Item 2(e):

    CUSIP Number: M4119S104

     

    Item 3:

    The reporting person is:

     

      (i)

    Waddell & Reed Financial, Inc., a parent holding company in accordance with Reg. 240.13d-1(b)(1)(ii)(G);

      (ii)

    Ivy Investment Management Company, an investment advisor in accordance with Reg. 240.13d-1(b)(1)(ii)(E).


    Item 4:

    Ownership

    The securities reported on herein are beneficially owned by one or more open-end investment companies or other managed accounts which are advised or sub-advised by Ivy Investment Management Company (“IICO”), an investment advisory subsidiary of Waddell & Reed Financial, Inc. (“WDR”). The investment advisory contracts grant IICO all investment and/or voting power over securities owned by such advisory clients. The investment sub-advisory contracts grant IICO investment power over securities owned by such sub-advisory clients and, in most cases, voting power. Any investment restriction of a sub-advisory contract does not restrict investment discretion or power in a material manner. Therefore, IICO may be deemed the beneficial owner of the securities covered by this statement under Rule 13d-3 of the Securities Exchange Act of 1934 (the “1934 Act”).

    IICO and WDR are of the view that they are not acting as a “group” for purposes of Section 13(d) under the 1934 Act. Indirect “beneficial ownership” is attributed to the respective parent companies solely because of the parent companies’ control relationship to IICO.

     

      (a)

    Amount beneficially owned: 2,757,223

     

      (b)

    Percent of class: 7.8

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole voting power to vote or to direct the vote:

     

          

    WDR: 2,757,223 (indirect)

          

    IICO: 2,757,223 (direct)

     

      (ii)

    Shared power to vote or to direct the vote: 0

     

      (iii)

    Sole power to dispose or to direct the disposition of:

     

          

    WDR: 2,757,223 (indirect)

          

    IICO: 2,757,223 (direct)

     

      (iv)

    Shared power to dispose or to direct the disposition of: 0

     

    Item 5:

    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following: [ ]


    Item 6:

    Ownership of More than Five Percent on Behalf of Another Person:

    The clients of IICO, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive dividends from, as well as the proceeds from the sale of, such securities. Ivy Science & Technology Fund, a company registered under the Investment Company Act of 1940, has an interest in more than 5% of the class of securities reported herein.

     

    Item 7:

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

     

        

    See Attached Exhibit 2.

     

    Item 8:

    Identification and Classification of Members of the Group:

     

        

    Not Applicable.

     

    Item 9:

    Notice of Dissolution of Group:

     

        

    Not Applicable.


    Item 10:

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 12, 2021

     

    Waddell & Reed Financial, Inc.  
    By: /s/ J.J. Richie  
    Name: J.J. Richie  
    Title: Attorney-In-Fact  
    Ivy Investment Management Company  
    By: /s/ J.J. Richie  
    Name: J.J. Richie  
    Title: Attorney-In-Fact  


    EXHIBIT INDEX

     

    Exhibit
    No.
       Description
    1    Joint Filing Agreement
    2    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
    3    Power of Attorney
    Get the next $EVGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVGN

    DatePrice TargetRatingAnalyst
    11/24/2021$8.00 → $7.00Outperform
    RBC Capital
    10/8/2021$7.00Buy
    ROTH Capital
    8/23/2021$8.00Outperform
    RBC Capital
    7/29/2021$10.00Buy
    Aegis Capital
    More analyst ratings

    $EVGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Ravzin Polina

    3 - Evogene Ltd. (0001574565) (Issuer)

    4/9/26 4:01:08 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 3 filed by Evogene Ltd

    3 - Evogene Ltd. (0001574565) (Issuer)

    3/18/26 9:23:02 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 3 filed by Evogene Ltd

    3 - Evogene Ltd. (0001574565) (Issuer)

    3/18/26 8:27:44 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

    Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical ActivityREHOVOT, Israel, June 2, 2026 /PRNewswire/ -- Evogene Ltd. ("Evogene") (NASDAQ:EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd., in combination with Nivolumab in patients with advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC).   The

    6/2/26 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Reports First Quarter 2026 Financial Results

    Conference call and webcast: today, May 20, 2026, 9:00 AM ETREHOVOT, Israel, May 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the first quarter ended March 31, 2026.  Mr. Ofer Haviv, President & CEO of Evogene, stated: "Following the strategic transformation initiated in 2025, we are now focused on execution and advancing our tech engine for small-molecule dis

    5/20/26 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene to Present at the 24th Schrödinger European User Group Meeting

    Conference will be held in Munich, Germany - May 19-21, 2026REHOVOT, Israel, May 12, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its participation in the 24th Schrödinger European User Group Meeting, taking place May 19–21, 2026, in Munich, Germany. Bringing together industry and academic experts to share advances and real-world applications in computational drug discovery, Evogene has been chosen to present its recent progress in generative design of novel compounds. Dr. Roberto Olender, Evogene's He

    5/12/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    SEC Filings

    View All

    SEC Form 424B3 filed by Evogene Ltd

    424B3 - Evogene Ltd. (0001574565) (Filer)

    5/20/26 8:45:28 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 6-K filed by Evogene Ltd

    6-K - Evogene Ltd. (0001574565) (Filer)

    5/20/26 7:00:14 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 6-K filed by Evogene Ltd

    6-K - Evogene Ltd. (0001574565) (Filer)

    5/18/26 4:01:21 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital reiterated coverage on EverGen Infrastructure with a new price target

    RBC Capital reiterated coverage of EverGen Infrastructure with a rating of Outperform and set a new price target of $7.00 from $8.00 previously

    11/24/21 7:31:39 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    ROTH Capital initiated coverage on Evogene with a new price target

    ROTH Capital initiated coverage of Evogene with a rating of Buy and set a new price target of $7.00

    10/8/21 8:30:09 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    RBC Capital initiated coverage on EverGen Infrastructure Corp. with a new price target

    RBC Capital initiated coverage of EverGen Infrastructure Corp. with a rating of Outperform and set a new price target of $8.00

    8/23/21 11:09:14 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Financials

    Live finance-specific insights

    View All

    Evogene Reports First Quarter 2026 Financial Results

    Conference call and webcast: today, May 20, 2026, 9:00 AM ETREHOVOT, Israel, May 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the first quarter ended March 31, 2026.  Mr. Ofer Haviv, President & CEO of Evogene, stated: "Following the strategic transformation initiated in 2025, we are now focused on execution and advancing our tech engine for small-molecule dis

    5/20/26 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Schedules First Quarter 2026 Financial Results Release

    Zoom conference call scheduled for May 20, 2026, 9:00 AM ETREHOVOT, Israel, May 7, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the first quarter 2026, on Wednesday, May 20, 2026. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).To attend the conference, please register in advance:https://www.veidan-conferencing.com/evogeneThe entire conference will be available online on the

    5/7/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

    Conference call and webcast: today, March 05, 2026, 9:00 AM ETREHOVOT, Israel, March 5, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the fourth quarter and full year ended December 31, 2025.    Mr. Ofer Haviv, President & CEO of Evogene, stated: "During 2025, we executed a clear and decisive strategic shift. After a comprehensive review of our technology assets, target markets, and capital allocation priorities, we sharpened our focus to drive sustainable long-term value by co

    3/5/26 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Leadership Updates

    Live Leadership Updates

    View All

    Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

    The collaboration is supported by a pan-European EUREKA grant, with participation of the Weizmann Institute of Science REHOVOT, Israel and MUNICH, Germany, Feb. 11, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Systasy Bioscience GmbH, a biotechnology company leveraging proprietary DNA barcoding technology for hyper-multiplexed pathway profiling in patient-derived iPSC models to accelerate drug discovery for complex disorders, and LMU University Hospital Munich, today announced a collaboration aiming to accelerate the devel

    2/11/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board

    Appointments Strengthen Scientific Leadership and Support the Acceleration of ChemPass AI™ for Drug and Ag-Chemical Discovery REHOVOT, Israel, Feb. 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational chemistry company focused on the AI-driven discovery and design of novel small molecules for the pharmaceutical and agricultural industries, today announced the appointment of Prof. John J. Irwin of the University of California, San Francisco (UCSF), and Prof. Dan T. Major of Bar-Ilan University (BIU) to its scientific advisory board (SAB). The

    2/9/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

    REHOVOT, Israel, Dec. 30, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, is pleased to announce the appointment of Dr. Olga Nissan as its Vice President of Business Development, effective as of January 1, 2026. Dr. Nissan is a seasoned biotechnology and pharmaceutical executive with extensive experience in bridging science, business, and funding. She has a proven track record of leading R&D, clinical develop

    12/30/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evogene Ltd

    SC 13G/A - Evogene Ltd. (0001574565) (Subject)

    10/15/24 6:52:26 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G filed by Evogene Ltd

    SC 13G - Evogene Ltd. (0001574565) (Subject)

    2/14/24 8:30:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G/A filed by Evogene Ltd (Amendment)

    SC 13G/A - Evogene Ltd. (0001574565) (Subject)

    2/11/22 12:15:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials